Winfred C Wang

List of Publications by Year
in descending order

139	9,168	57631	40881
papers	citations	44 h-index	93 g-index

143	143	143	4220
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nocturnal Enuresis in Sickle Cell: Sociodemographic, Medical, and Quality of Life Factors. Journal of Pediatric Psychology, 2022, 47, 75-85.	1.1	2
2	Hematologic complications with age in Shwachman-Diamond syndrome. Blood Advances, 2022, 6, 297-306.	2.5	23
3	Reading intervention targeting phonemic awareness and symbol imagery in children with sickle cell disease. Pediatric Blood and Cancer, 2022, 69, e29561.	0.8	0
4	Fetal hemoglobin modulates neurocognitive performance in sickle cell anemiaâœ°,âœ°âœ°. Current Research in Translational Medicine, 2022, 70, 103335.	1.2	3
5	Cognitive performance as a predictor of healthcare transition in sickle cell disease. British Journal of Haematology, 2021, 192, 1082-1091.	1.2	13
6	Eltrombopag in children with severe aplastic anemia. Pediatric Blood and Cancer, 2021, 68, e29066.	0.8	11
7	Gabapentin for acute pain in sickle cell disease: A randomized doubleâ€blinded placeboâ€controlled phase II clinical trial. EJHaem, 2021, 2, 327-334.	0.4	3
8	What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study. British Journal of Haematology, 2021, 194, 463-468.	1.2	6
9	Generalization of a genetic risk score for time to first albuminuria in children with sickle cell anaemia: SCCRIP cohort study results. British Journal of Haematology, 2021, 194, 469-473.	1.2	1
10	Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood. British Journal of Haematology, 2021, 195, 256-266.	1.2	30
11	Effects of hydroxyurea on brain function in children with sickle cell anemia. Pediatric Blood and Cancer, 2021, 68, e29254.	0.8	14
12	Progression of central nervous system disease from pediatric to young adulthood in sickle cell anemia. Experimental Biology and Medicine, 2021, 246, 2473-2479.	1.1	4
13	Developmental screening of threeâ€yearâ€old children with sickle cell disease compared to controls. British Journal of Haematology, 2021, 195, 621-628.	1.2	3
14	Use of Wise Device Technology to Measure Adherence to Hydroxyurea Therapy in Youth With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2021, 43, e19-e25.	0.3	3
15	A metaâ€analysis of toxicities related to hydroxycarbamide dosing strategies. EJHaem, 2020, 1, 235-238.	0.4	1
16	Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. The Cochrane Library, 2020, 2020, CD003146.	1.5	11
17	Association between hydroxycarbamide exposure and neurocognitive function in adolescents with sickle cell disease. British Journal of Haematology, 2020, 189, 1192-1203.	1.2	23
18	Splenic function is not maintained long-term after partial splenectomy in children with sickle cell disease. Journal of Pediatric Surgery, 2020, 55, 2471-2474.	0.8	2

#	Article	IF	Citations
19	High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia. Haematologica, 2020, 106, 295-298.	1.7	9
20	Food Deserts Are Associated with Acute Care Utilization Among Preschool Children with Sickle Cell Disease. Blood, 2020, 136, 19-19.	0.6	0
21	Fetal Hemoglobin Mediates the Effect of Beta Globin Gene Polymorphisms on Neurocognitive Functioning in Sickle Cell Disease. Blood, 2020, 136, 23-24.	0.6	0
22	Acute Chest Syndrome After Splenectomy in Children With Sickle Cell Disease. Journal of Surgical Research, 2019, 242, 336-341.	0.8	4
23	Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. Haematologica, 2019, 104, 1974-1983.	1.7	43
24	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	1.7	46
25	The Case for Pharmacogeneticsâ€Guided Prescribing of Codeine in Children. Clinical Pharmacology and Therapeutics, 2019, 105, 1300-1302.	2.3	12
26	Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. American Journal of Hematology, 2019, 94, E27-E29.	2.0	19
27	Neurocognitive Impairment Predicts Poor Transition Outcomes Among Patients with Sickle Cell Disease. Blood, 2019, 134, 519-519.	0.6	0
28	Progression of Central Nervous System Vasculopathy in Young Adults with Sickle Cell Anemia. Blood, 2019, 134, 2290-2290.	0.6	0
29	Transcranial Doppler Velocities Conversion Rate Based on Increasing Hemoglobin Concentration: Analyses from the SCCRIP Cohort Study. Blood, 2019, 134, 1002-1002.	0.6	0
30	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood, 2018, 131, 2183-2192.	0.6	121
31	Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. Pediatric Blood and Cancer, 2018, 65, e27228.	0.8	57
32	Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease. Blood, 2018, 132, 509-509.	0.6	4
33	Precision Medicine for Sickle Cell Disease through Whole Genome Sequencing. Blood, 2018, 132, 3641-3641.	0.6	3
34	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. Blood, 2018, 132, 4807-4807.	0.6	1
35	The Shwachman-Diamond Syndrome Registry: Hematologic Complications. Blood, 2018, 132, 3871-3871.	0.6	0
36	Operative and Immediate Postoperative Differences Between Traditional Multiport and Reduced Port Laparoscopic Total Splenectomy in Pediatric Patients. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2017, 27, 206-210.	0.5	4

#	Article	IF	Citations
37	Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. The Cochrane Library, 2017, 1, CD003146.	1.5	17
38	A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. American Journal of Hematology, 2017, 92, 1333-1339.	2.0	66
39	Clinic Attendance of Youth With Sickle Cell Disease on Hydroxyurea Treatment. Journal of Pediatric Hematology/Oncology, 2017, 39, 345-349.	0.3	4
40	Removal of Arterial Vessel Contributions in Susceptibility-Weighted Images for Quantification of Normalized Visible Venous Volume in Children with Sickle Cell Disease. Journal of Healthcare Engineering, 2017, 2017, 1-8.	1.1	1
41	Effects of Hydroxyurea (HU) on Neurocognitive Performance in Children with Sickle Cell Disease: A Prospective Trial. Blood, 2017, 130, 760-760.	0.6	3
42	Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor. Blood, 2017, 130, 689-689.	0.6	4
43	The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD). Blood, 2017, 130, 980-980.	0.6	1
44	Birth Prevalence of Sickle Cell Trait and Sickle Cell Disease in Shelby County, TN. Pediatric Blood and Cancer, 2016, 63, 1054-1059.	0.8	5
45	Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia. British Journal of Haematology, 2016, 175, 331-338.	1.2	26
46	Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease. Experimental Biology and Medicine, 2016, 241, 730-736.	1.1	11
47	Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study. Clinical Trials, 2016, 13, 409-416.	0.7	14
48	Distance from an Urban Sickle Cell Center and its Effects on Routine Healthcare Management and Rates of Hospitalization. Hemoglobin, 2016, 40, 10-15.	0.4	6
49	Hydroxyurea at Maximal Tolerated Dose (MTD) Prior to Completion of the Î²-Globin Switch Has Additive but Not Sustained Benefits in Fetal Hemoglobin Production. Blood, 2016, 128, 125-125.	0.6	0
50	Iron Overload Is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD). Blood, 2016, 128, 2430-2430.	0.6	1
51	Paroxysmal cold hemoglobinuria due to an IgA Donathâ€“Landsteiner antibody. Pediatric Blood and Cancer, 2015, 62, 2044-2046.	0.8	5
52	Silent cerebral infarcts in very young children with sickle cell anaemia are associated with a higher risk of stroke. British Journal of Haematology, 2015, 171, 120-129.	1.2	37
53	Newborn screening for sickle cell disease: necessary but not sufficient. Jornal De Pediatria (VersÃ£o Em) Tj ETQq1 1 0.784314 rgBT /O	0.2	0
54	Newborn screening for sickle cell disease: necessary but not sufficient. Jornal De Pediatria, 2015, 91, 210-212.	0.9	6

#	Article	IF	Citations
55	Prognostic Factors for Hospitalization of Children with Sickle Cell Anemia Treated with Hydroxyurea at Maximum Tolerated Dose. Blood, 2015, 126, 2177-2177.	0.6	0
56	Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. European Journal of Haematology, 2014, 93, 377-383.	1.1	25
57	From Infancy to Adolescence. Medicine (United States), 2014, 93, e215.	0.4	59
58	Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): An initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC). Pediatric Blood and Cancer, 2014, 61, 869-874.	0.8	31
59	Immunologic Effects of Hydroxyurea in Sickle Cell Anemia. Pediatrics, 2014, 134, 686-695.	1.0	37
60	Hydroxyurea and Growth in Young Children With Sickle Cell Disease. Pediatrics, 2014, 134, 465-472.	1.0	35
61	Transplant Outcome of Pediatric and Young Adult Patients with Aplastic Anemia: St Jude Childrenâ€™s Research Hospital Experience. Blood, 2014, 124, 1210-1210.	0.6	0
62	Brain MRI/MRA Findings after Hydroxyurea Treatment in Children with Sickle Cell Anemia. Blood, 2014, 124, 89-89.	0.6	0
63	High Failure Rate with Brigance Developmental Screening in 3 Year-Old Children with Sickle Cell Disease. Blood, 2014, 124, 4926-4926.	0.6	0
64	Comparison of hematologic measurements between local and central laboratories: Data from the BABY HUG trial. Clinical Biochemistry, 2013, 46, 278-281.	0.8	9
65	Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. American Journal of Hematology, 2013, 88, 571-576.	2.0	71
66	Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. , 2013, , CD003146.		39
67	Hydroxyurea treatment of children with hemoglobin SC disease. Pediatric Blood and Cancer, 2013, 60, 323-325.	0.8	19
68	Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. British Journal of Haematology, 2013, 161, 402-405.	1.2	40
69	Developmental Function in Toddlers With Sickle Cell Anemia. Pediatrics, 2013, 131, e406-e414.	1.0	42
70	Hydroxyurea Is Associated With Lower Costs of Care of Young Children With Sickle Cell Anemia. Pediatrics, 2013, 132, 677-683.	1.0	77
71	Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program. PLoS ONE, 2013, 8, e72077.	1.1	32
72	Escalating Doses Of Hydroxyurea In Very Young Children With Sickle Cell Anemia. Blood, 2013, 122, 978-978.	0.6	0

#	Article	IF	Citations
73	Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood, 2012, 120, 4304-4310.	0.6	204
74	Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management. Scientific World Journal, The, 2012, 2012, 1-55.	0.8	125
75	Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood and Cancer, 2012, 59, 170-172.	0.8	13
76	Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study. Pediatric Blood and Cancer, 2012, 59, 675-678.	0.8	42
77	Effect of hydroxyurea treatment on renal function parameters: Results from the multiâ€center placeboâ€controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood and Cancer, 2012, 59, 668-674.	0.8	94
78	Effects of Hydroxyurea (HU) On Lymphocyte Subsets and the Immune Response to Pneumococcal, Measles, Mumps and Rubella Vaccination in the Pediatric Hydroxyurea Phase III Clinical Trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood, 2012, 120, 243-243.	0.6	6
79	Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet, The, 2011, 377, 1663-1672.	6.3	647
80	Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood, 2011, 117, 2614-2617.	0.6	95
81	The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multiâ€centre CHAMPS trial. British Journal of Haematology, 2011, 152, 771-776.	1.2	30
82	Hemodynamic responses to visual stimulation in children with sickle cell anemia. Brain Imaging and Behavior, 2011, 5, 295-306.	1.1	28
83	Neurocognitive screening with the Brigance Preschool screenâ€ in 3â€yearâ€old children with sickle cell disease. Pediatric Blood and Cancer, 2011, 56, 620-624.	0.8	22
84	Sickleâ€cell disease and compromised cognition. Pediatric Blood and Cancer, 2011, 56, 705-706.	0.8	6
85	Hydroxyurea Treatment of Young Children with Sickle Cell Anemia: Safety and Efficacy of Continued Treatment â€“ the BABY HUG Follow-up Study. Blood, 2011, 118, 7-7.	0.6	4
86	The Impact of Hydroxyurea Therapy on the Prevalence of Retinopathy in a Pediatric Sickle Cell Cohort. Blood, 2011, 118, 1057-1057.	0.6	0
87	Costs Associated with the Care of Very Young Children with Sickle Cell Anemia (SCA): Analysis from the BABY HUG Study. Blood, 2011, 118, 171-171.	0.6	0
88	The Physiological and Clinical Effects of Interrupting a Treatment Regimen of Hydroxyurea in Young Children with Sickle Cell Anemia (SCA). Blood, 2011, 118, 2134-2134.	0.6	0
89	Sickle cell disease in children. Clinical Advances in Hematology and Oncology, 2011, 9, 554-6.	0.3	0
90	Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: Baseline data from the BABY HUG trial. Pediatric Blood and Cancer, 2010, 54, 256-259.	0.8	38

#	Article	IF	Citations
91	Renal Function in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial. Journal of Pediatrics, 2010, 156, 66-70.e1.	0.9	109
92	Urine concentrating ability in infants with sickle cell disease: Baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood and Cancer, 2010, 54, 265-268.	0.8	23
93	The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design. Pediatric Blood and Cancer, 2010, 54, 250-255.	0.8	51
94	Influence of Hemoglobin Level on Clinical Findings In Infants with Sickle Cell Anemia: Data From BABY HUG. Blood, 2010, 116, 1631-1631.	0.6	1
95	Effects of Hydroxyurea (HU) and Magnesium Pidolate (Mg) in Hemoglobin SC Disease (HbSC): the â€œCHAMPSâ€•Trial.. Blood, 2009, 114, 819-819.	0.6	5
96	A Pilot Study of Tapered Oral Dexamethasone for the Acute Chest Syndrome of Sickle Cell Disease.. Blood, 2009, 114, 1515-1515.	0.6	0
97	Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatric Blood and Cancer, 2008, 50, 293-297.	0.8	81
98	Evaluation of a comprehensive transcranial doppler screening program for children with sickle cell anemia. Pediatric Blood and Cancer, 2008, 50, 818-821.	0.8	76
99	Biloma and pneumobilia in sickle cell disease. Pediatric Blood and Cancer, 2008, 51, 288-290.	0.8	7
100	MRI abnormalities of the brain in oneâ€yearâ€old children with sickle cell anemia. Pediatric Blood and Cancer, 2008, 51, 643-646.	0.8	72
101	The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. British Journal of Haematology, 2008, 142, 94-99.	1.2	50
102	The pharmacotherapy of sickle cell disease. Expert Opinion on Pharmacotherapy, 2008, 9, 3069-3082.	0.9	10
103	Central Nervous System Complications of Sickle Cell Disease in Children: An Overview. Child Neuropsychology, 2007, 13, 103-119.	0.8	29
104	The pathophysiology, prevention, and treatment of stroke in sickle cell disease. Current Opinion in Hematology, 2007, 14, 191-197.	1.2	60
105	Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: A retrospective cohort study of 137 children with sickle cell anemia. Journal of Pediatrics, 2006, 149, 710-712.	0.9	135
106	Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood, 2005, 106, 2269-2275.	0.6	251
107	Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. British Journal of Haematology, 2005, 129, 550-552.	1.2	59
108	Sickle cell hepatopathy: Clinical presentation, treatment, and outcome in pediatric and adult patients. Pediatric Blood and Cancer, 2005, 45, 184-190.	0.8	114

#	Article	IF	Citations
109	Effect of Long-term Transfusion on Growth in Children with Sickle Cell Anemia: Results of the Stop Trial. Journal of Pediatrics, 2005, 147, 244-247.	0.9	78
110	Comparison of Transcranial Doppler Sonography With and Without Imaging in the Evaluation of Children With Sickle Cell Anemia. American Journal of Roentgenology, 2004, 183, 1117-1122.	1.0	40
111	Brain Imaging Findings in Pediatric Patients with Sickle Cell Disease. Radiology, 2003, 228, 216-225.	3.6	144
112	Alpha Thalassemia is Associated With Decreased Risk of Abnormal Transcranial Doppler Ultrasonography in Children With Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 2003, 25, 622-628.	0.3	85
113	Cognitive impairment in children with hemoglobin SS sickle cell disease: relationship to MR imaging findings and hematocrit. American Journal of Neuroradiology, 2003, 24, 382-9.	1.2	99
114	Kindergarten Readiness Skills in Children With Sickle Cell Disease: Evidence of Early Neurocognitive Damage?. Journal of Child Neurology, 2002, 17, 111-116.	0.7	35
115	Blood transfusion for preventing stroke in people with sickle cell disease. , 2002, , CD003146.		12
116	Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood, 2002, 99, 10-14.	0.6	154
117	Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood, 2002, 99, 3014-3018.	0.6	319
118	Effect of hydroxyurea on growth in children with sickle cell anemia: Results of the HUG-KIDS study. Journal of Pediatrics, 2002, 140, 225-229.	0.9	89
119	Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. Journal of Pediatrics, 2002, 140, 348-354.	0.9	215
120	Neuropsychologic performance in school-aged children with sickle cell disease: A report from the Cooperative Study of Sickle Cell Disease. Journal of Pediatrics, 2001, 139, 391-397.	0.9	248
121	Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: A report from the Cooperative Study of Sickle Cell Disease. Journal of Pediatrics, 2001, 139, 385-390.	0.9	256
122	A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. Journal of Pediatrics, 2001, 139, 790-796.	0.9	165
123	Improved cerebrovascular patency following therapy in patients with sickle cell disease: Initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Annals of Neurology, 2001, 49, 222-229.	2.8	41
124	Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. British Journal of Haematology, 2000, 109, 322-327.	1.2	119
125	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN THE TREATMENT OF NEONATES WITH NEUTROPENIA AND SEPSIS. Pediatric Hematology and Oncology, 2000, 17, 469-473.	0.3	2
126	Prediction of Adverse Outcomes in Children with Sickle Cell Disease. New England Journal of Medicine, 2000, 342, 83-89.	13.9	446

#	Article	IF	Citations
127	Subtle brain abnormalities in children with sickle cell disease: Relationship to blood hematocrit. Annals of Neurology, 1999, 45, 279-286.	2.8	94
128	Stroke Prevention Trial in Sickle Cell Anemia. Contemporary Clinical Trials, 1998, 19, 110-129.	2.0	228
129	Quantitative MRI of the brain in children with sickle cell disease reveals abnormalities unseen by conventional MRI. Journal of Magnetic Resonance Imaging, 1998, 8, 535-543.	1.9	54
130	Abnormalities of the central nervous system in very young children with sickle cell anemia. Journal of Pediatrics, 1998, 132, 994-998.	0.9	98
131	Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography. New England Journal of Medicine, 1998, 339, 5-11.	13.9	1,699
132	Quantitative MR imaging of children with sickle cell disease: Striking T1 elevation in the thalamus. Journal of Magnetic Resonance Imaging, 1996, 6, 226-234.	1.9	9
133	A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. British Journal of Haematology, 1995, 89, 380-385.	1.2	114
134	Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. Journal of Pediatrics, 1995, 126, 896-899.	0.9	346
135	Developmental Screening in Young Children with Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 1993, 15, 87-91.	0.3	30
136	High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. Journal of Pediatrics, 1991, 118, 377-382.	0.9	168
137	Lymphocyte and complement abnormalities in splenectomized patients with hematologic disorders. American Journal of Hematology, 1988, 28, 239-245.	2.0	16
138	Lymphocyte phenotype and function in chronically transfused children with sickle cell disease. American Journal of Hematology, 1985, 20, 31-40.	2.0	20
139	Immunoregulatory abnormalities in evans syndrome. American Journal of Hematology, 1983, 15, 381-390.	2.0	58